• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Orexo touts PK data for intranasal opioid overdose reversal drug

January 7, 2019 By Sarah Faulkner

Orexo updated logoOrexo (STO:ORX) touted results today from a 20-person pharmacokinetic study of its OX124-001 naloxone nasal spray.

The company’s product is designed to reverse opioid overdoses. In the PK study, Orexo compared its drug to Narcan – the market-leading naloxone rescue medication.

Sweden-based Orexo reported that all formulations of OX124 were well-tolerated by study participants and showed “substantially higher” plasma concentrations of naloxone compared to Narcan. OX124 also had sustained duration of elevated plasma concentrations and equivalent or superior onset time compared to Narcan, according to Orexo.

In a statement, the company said it plans to develop a proprietary rescue drug “capable of reversing any overdose, irrespective of which type of opioid has caused it.”

“OX124 forms part of our important work to tackle the opioid crisis in the US, and I am very encouraged by the positive results generated by our R&D team. We look forward to advancing OX124 and OX125 and remain confident that we will be able to develop a product for opioid overdose reversal, in line with our strategy to expand our US commercial footprint,” president & CEO Nikolaj Sørensen said in prepared remarks.

“We are very pleased with the positive results from the PK study which demonstrate OX124’s potential to improve the ability to reverse the effect of the most powerful synthetic opioids. The results also pave the way for Orexo to develop a new technology platform that shows great promise for further product development,” Robert Rönn, VP & head of R&D, added.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: orexo

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS